OTTAWA, Dec. 10, 2019 /CNW/ - The changes to how the Patented Medicines Prices Review Board (PMPRB) calculates maximum prices allowed for such treatments in Canada, approved in … The Patented Medicine Prices Review aboard (PMPRB) has extended the deadline for written submissions on new Draft Guidelines until January 31, 2020.Originally, the consultation was scheduled to run until January 20, 2020. As we reported, the Board proposed Draft Guidelines to replace its existing price-review practices, including the Compendium of Policies, Guidelines and Procedures. Background. new factors for the PMPRB to consider in setting pricing, such as pharmacoeconomic value, for medicines with a Drug Identification Number (DIN) issued on or after August 21, 2019; new reporting requirements relating to rebates provided to direct or indirect purchasers, or reimbursing bodies, such as public or private drug plans; and • Using new drug contribution to GDP and GDP growth over the last five years, the PMPRB is estimating a threshold of $20M per new drug. • New Category 1 drugs with an estimated market size that exceeds this threshold within any of its first five years of sale will require further price adjustments. 1100 René-Lévesque Blvd W. Montreal, QC H3B 4X9 (514) 392-9000 The government and the insurance industry have argued that the PMPRB needs the additional regulatory powers because the prices of patented medicines are causing a sustainability crisis for private insurers in Canada. The new rules are expected to reduce average maximum allowable prices by 52% to 84% from the current regulated price ceiling. The Patented Medicine Prices Review Board Standard Life Centre, Box L40 333 Laurier Avenue West, Suite 1400 Ottawa, ON K1P 1C1 Tel. PMPRB thresholds. New Medicines info and details found on MORSE Consulting Inc. New Medicines info and details found on MORSE Consulting Inc. HOME. Among new products, oncology medicines would require average price reductions of 60.8 % (range 22% - 86%) from PMPRB’s current non-excessive levels. New Price Regulatory Factors (new s. 4.4): The amendments will provide the PMPRB with three new price regulatory factors: i) pharmacoeconomic value, ii) market size, and iii) gross domestic product (GDP) in Canada and GDP per capita in Canada. 2) for most new patented medicines, combined with reductions from current non-excessive levels to the median international price for existing patented medicines.